Qu Biologics is very pleased to have engaged the following experts in gastroenterology to provide guidance and oversight of its IBD clinical trials:
Dr. Bressler is a Clinical Assistant Professor of Medicine, in the Division of Gastroenterology at the University of British Columbia’s Department of Medicine. Dr. Bressler received his MD from the University of British Columbia and completed his residency in internal medicine and gastroenterology at the University of Toronto. He received an MS in Epidemiology from the Harvard Public School of Health and completed an advanced fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital, Harvard Medical School. Dr. Bressler is a recognized expert in inflammatory bowel disease. His research interests include population based studies, classic clinical epidemiology studies and clinical trials in inflammatory bowel disease. He is an invited reviewer for many medical journals including Gastroenterology, Clinical Gastroenterology and Hepatology, and American Journal of Gastroenterology. Dr. Bressler is a member of Qu Biologics’ Scientific Advisory Board.
A recipient of numerous awards, research fellowships and grants, Dr. Richard N. Fedorak is an internationally recognised expert in inflammatory bowel disease. He has an active basic gastrointestinal research laboratory in the area of mucosal immunology, inflammation, and membrane function and structure and leads a large gastrointestinal disease clinical research group. Dr. Fedorak serves on multiple national and international scientific advisory boards. He has published over 500 peer-reviewed manuscripts and book chapters, produced two patents on colonic-specific drug delivery, and has lectured around the world. He has multiple grant review committee memberships and editorial positions with front ranked gastrointestinal journals. Currently, Dr. Fedorak is Associate Vice President (Research) and Professor of Medicine in the Division of Gastroenterology at the University of Alberta and also serves as Director for both the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) and the Northern Alberta Clinical Trials and Research Centre (NACTRC). In addition, Dr. Fedorak is President of the Canadian Digestive Health Foundation (CDHF) and Chairman of the Research Committee, World Gastroenterology Organization. Dr. Fedorak received his medical degree with First Class Honours from the University of Alberta. His Gastroenterology Clinical and Research Fellowship training was carried out at the University of Chicago and Columbia University, New York.
Dr. Panaccione is currently a Professor of Medicine at the University of Calgary and the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary as well as Director of Gastroenterology Research for the Division of Gastroenterology and Hepatology. He is a recognized international expert in the diagnosis, management, and treatment of inflammatory bowel disease. Dr. Panaccione sits on many editorial boards and serves as a reviewer for the New England Journal of Medicine, Gastroenterology, Gut, APT, and Inflammatory Bowel Diseases. He has lectured across North America on various topics in inflammatory bowel disease and has delivered over 175 lectures in the last five years. He has been elected to the International Organization of IBD (IOIBD) and has received the highest award, the Finklestein award for this contribution to the field of IBD by Crohn’s and Colitis Canada. Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999.
Dr. William Sandborn is an internationally recognized expert in the conduct of clinical trials in inflammatory bowel disease. Currently, Dr. Sandborn is a Professor of Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He directs a large research unit where his supervises a multi-investigator team specializing in inflammatory bowel disease clinical trials. Dr. Sandborn has published over 447 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease. Dr. Sandborn completed a gastroenterology fellowship at the Mayo Clinic, where he also held positions of Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. He completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.